Key Segments:
By Application
-
Oncology
-
Cardiology
-
Paediatrics
-
Endocrinology
-
Respiratory Medicine
-
Rare Genetic Disorders
-
Infectious Diseases
-
Other Applications
By Products And Services
-
Instruments and Equipment
-
Consumables
-
Services (Genomic Testing, Data Analysis, Interpretation, Genetic Counselling)
By Technology
-
Next-Generation Sequencing (NGS)
-
Polymerase Chain Reaction (PCR)
-
Microarray
-
Sanger Sequencing
-
Others
By End-User
-
Hospitals & Clinics
-
Academic Institutions
-
Research Institutions
-
Diagnostic Laboratories
-
Pharmaceutical & Biotechnology Companies
-
Other End-Users
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Rising cancer incidence combined with expanding use of genomic-driven targeted therapies and government-funded national genomic programs.
North America dominates with about 42.62% of global revenue, led by the United States.
Oncology leads with approximately 38% market share, driven by widespread use of genomic tests for cancer diagnosis and treatment selection.
The market was valued at USD 33.3 billion in 2025.
The market is expected to grow at a CAGR of 14.64% from 2026 to 2035.